Evaluation of the effects of Resveratrol Supplementation on Hepatic Enzymes, Inflammatory Factors, Lipid profile, blood glucose, Insulin Sensitivity, and Hepatic fibrosis in patients with Nonalcoholic Fatty Liver Disease.

Evaluating the effect of Resveratrol supplement on lipid profile, hepatic enzymes, inflammatory factors, and hepatic fibrosis in patients with Nonalcoholic Fatty Liver Disease (NAFLD)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202014010N7

Enrollment

Registered

2013-01-11

Start date

2012-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver. Inflammatory liver disease, unspecified

Interventions

Intervention 1: Intervention: Soft gel Resveratrol 500 mg once a day /12 weeks. Intervention 2: Placebo: Edible paraffin soft gelonce a day/ 12 weeks.

Treatment - Drugs

Placebo

Intervention: Soft gel Resveratrol 500 mg once a day /12 weeks

Placebo: Edible paraffin soft gelonce a day/ 12 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 18 and older; Evidence of nonalcoholic steatohepatitis with steatosis grade higher or equal to 1 in ultrasonography; No history of Alcohol consumption or consuming less than 10 grams alcohol per day in women and less than 20 grams per day in men; Absence of other liver disorders, malignancies, cardiovascular, respiratory, and kidney disorders; Absence of pregnancy or lactation; Absence of taking any medications in the past three months; Absence of weight loss in the recent three months; Absence of endocrine and metabolism disorders. Exclusion criteria: Weight loss more than 10% of baseline body weight during the intervention period. Pregnancy; Disliking to continue the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver Enzymes. Timepoint: at the first and at the 12th week of the study. Method of measurement: Biochemical analysis.	—

Secondary

Measure	Time frame
Liver fibrosis. Timepoint: at the first and the end of the study. Method of measurement: Fibroscan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Azita Hekmatdoost

National Nutrition and Food Technology Research Institute

a_hekmat2000@yahoo.com+98 21 2236 0656

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026